-
UPDATE: BMO Capital Starts Seagen (SGEN) at Market Perform
-
Seattle Genetics (SGEN) PT Raised to $154 at BMO Capital on Tukysa FDA Approval
-
BMO Capital Starts Seattle Genetics (SGEN) at Outperform
-
Notable Analyst Rating Changes 09/07: (BCS) (RKT) (PTEN) Upgraded; (NVDA) (WY) (SGEN) Downgraded
-
Notable Analyst Rating Changes 07/05: (BX) (YNDX) (TKC) Upgraded; (AMD) (MT) (BAM) Downgraded
-
Notable Analyst Rating Changes 11/11: (LSCC) (GNW) (DNDN) Upgraded; (CAG) (BRLI) (FSLR) Downgraded
-
Notable Analyst Rating Changes 09/16: (EBAY) (LYG) (REV) Upgraded; (RIMM) (ADBE) (SSYS) Downgraded
-
Notable Analyst Rating Changes 08/31: GPS, ANF, BMY, UBS Upgraded; HPQ, DGIT, RAX, POT Downgraded
-
Notable Analyst Rating Changes 6/19: AIG, KMX, TOT Upgraded; KFT, AGU, UBS, CVH Downgraded